Up a level |
Alhassan, Yussif, Twimukye, Adelline, Malaba, Thoko, Orrell, Catherine, Myer, Landon, Waitt, Catriona ORCID: 0000-0003-0134-5855, Lamorde, Mohammed, Kambugu, Andrew, Reynolds, Helen ORCID: 0000-0001-7443-4520, Khoo, Saye et al (show 1 more authors)
(2020)
Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and Uganda.
BMC Public Health, 20 (1).
1883-.
Alhassan, Yussif, Twimukye, Adelline, Malaba, Thoko, Orrell, Catherine, Myer, Landon, Waitt, Catriona ORCID: 0000-0003-0134-5855, Lamorde, Mohammed, Kambugu, Andrew, Reynolds, Helen ORCID: 0000-0001-7443-4520, Khoo, Saye et al (show 1 more authors)
(2020)
Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: a qualitative study with stakeholders in South Africa and Uganda.
BMC HEALTH SERVICES RESEARCH, 20 (1).
705-.
Hakim, James G, Thompson, Jennifer, Kityo, Cissy, Hoppe, Anne, Kambugu, Andrew, van Oosterhout, Joep J, Lugemwa, Abbas, Siika, Abraham, Mwebaze, Raymond, Mweemba, Aggrey et al (show 7 more authors)
(2017)
Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.
The Lancet. Infectious diseases, 18 (1).
pp. 47-57.
Ahmad, Raheelah, Atun, Rifat A, Birgand, Gabriel, Castro-Sanchez, Enrique, Charani, Esmita ORCID: 0000-0002-5938-1202, Ferlie, Ewan B, Hussain, Izhar, Kambugu, Andrew, Labarca, Jaime, Hara, Gabriel Levy et al (show 7 more authors)
(2021)
Macro level influences on strategic responses to the COVID-19 pandemic - an international survey and tool for national assessments.
JOURNAL OF GLOBAL HEALTH, 11.
05011-.
Paton, Nicholas I, Kityo, Cissy, Thompson, Jennifer, Nankya, Immaculate, Bagenda, Leonard, Hoppe, Anne, Hakim, James, Kambugu, Andrew, van Oosterhout, Joep J, Kiconco, Mary et al (show 5 more authors)
(2017)
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.
The lancet. HIV, 4 (8).
e341-e348.
Charani, Esmita ORCID: 0000-0002-5938-1202, McKee, Martin, Ahmad, Raheelah, Balasegaram, Manica, Bonaconsa, Candice, Merrett, Gemma Buckland, Busse, Reinhard, Carter, Vanessa, Castro-Sanchez, Enrique, Franklin, Bryony D et al (show 18 more authors)
(2021)
Optimising antimicrobial use in humans-review of current evidence and an interdisciplinary consensus on key priorities for research.
LANCET REGIONAL HEALTH-EUROPE, 7.
100161-.